Verge genomics tests new drug VRG50635 for safety in 22 volunteers
Knowledge-focused
Completed
This completed Phase 1 trial tested the safety and how the body absorbs VRG50635 in 22 healthy adults aged 19 to 55. Participants received either the drug or a placebo. The study focused on side effects and drug levels in the blood, not on treating any disease.
Phase: PHASE1 • Sponsor: Verge Genomics • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC